Kymera Therapeutics Inc. has unveiled a corporate presentation focusing on their advancements in the field of immunology, particularly through the use of oral medicines. The company is at the forefront of Targeted Protein Degradation $(TPD.AU)$ and is recognized for its capabilities in developing oral degraders that target traditionally undrugged areas within validated pathways. Their approach aims to deliver therapies with biologics-like profiles, potentially expanding access to millions of patients globally. Kymera has introduced five new investigational degrader drugs to clinical trials since 2020 and plans to have a total of ten by 2026. The company has dosed over 400 participants in their clinical pipeline, demonstrating strong translation from preclinical to clinical outcomes. Kymera's strategy also seeks to replace injectable biologics and offer more convenient therapies to the 97% of patients who are underserved in the immunology market. You can access the full presentation through the link below.